Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

t and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.  A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 9488233.  The webcast and telephone replay will be available through September 29, 2011.  

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Forward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different fro
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... This news release is available in German . ... at the Technische Universitt Mnchen (TUM) have demonstrated a ... Their experiments show that future computer chips could be ... transistors. As the main enabling technology of the semiconductor ... fundamental limits, the TUM researchers and collaborators at the ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... made of clay and a bit of high-grade plastic draws oil ... lab tests show that oil absorbed can be squeezed back out ... the material, called an aerogel, believe it will effectively clean up ... and roadways, rivers and oceans. , The EPA estimates that 10 ...
... Feb. 4, 2010 -- Four Oak Ridge National Laboratory ... five-year research grants as part of the Department of ... million program, funded under the American Recovery and Reinvestment ... to support exceptional researchers during the crucial early career ...
... , , IPSWICH, Mass. ... to the Wellcome Trust Sanger Institute, New England Biolabs is ... England Biolabs as one of its suppliers for next-generation sequencing ... "We are extremely pleased that the Wellcome Trust Sanger Institute, ...
Cached Biology Technology:New material absorbs, conserves oil 24 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing 2
(Date:9/30/2014)... do seedless watermelon, salmon, and strawberries all have in ... two sets of chromosomes and are diploid, these organisms ... sets of chromosomesseedless watermelon and salmon have 3 and ... While this might seem surprising, in fact most ... first discovered over a century ago, but only recently, ...
(Date:9/30/2014)... A team of environmental scientists and engineers, led ... awarded a three-year, $5.25 million grant from the ... Competitive Research to make a direct positive impact ... remediation and disposal of radioactive contaminants. , "Understanding ... adequately dealing with environmental aspects of nuclear technologies ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Researchers get $5.25 million to advance nuclear technologies in South Carolina 2On the trail of the truffle flavor 2
... The biggest ever single UK public investment in bioenergy ... main funding agency for the biosciences the Biotechnology ... 27M BBSRC Sustainable Bioenergy Centre has been launched to ... and emerging UK sustainable bioenergy sector and to ...
... Switzerland, Jan. 26 SVOX, the leading provider ... the Professional,Speech Processing Group of Siemens AG, according ... speech technology-related IP of Siemens AG developed,over 25 ... more than 60 patent families. The majority of ...
... Spring Harbor Laboratory (CSHL) announced today the discovery of ... time, they reported that their discovery suggests the presence ... in which these and possibly other small RNAs are ... project called ENCODE, also provided information concerning the biological ...
Cached Biology News:Biggest ever public investment in bioenergy to help provide clean, green and sustainable fuels 2SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2CSHL scientists find a new class of small RNAs and define its function 2CSHL scientists find a new class of small RNAs and define its function 3
Request Info...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
Biology Products: